Zelira Therapeutics Ltd. · ASX:ZLD
Zelira Therapeutics — Non-Deal Roadshow (October 2020)
17 slides from Zelira Therapeutics's roadshow presentation, Oct 22, 2020
Slide 1: Zelira Therapeutics: A Global Biopharmaceutical Company
For personal use only ZELIRA THERAPEUTICS A GLOBAL BIOPHARMACEUTICAL COMPANY DEVELOPING AND MARKETING CLINICALLY VALIDATED CANNABIS MEDICINES ASX: ZLD OTCQ B : Z L DA F W W W. Z E L I R AT X .CO M
Slide 2: Disclaimer & Important Notice
DISCLAIMER & IMPORTANT NOTICE For personal use only Disclaimer This presentation has been prepared by Zelira Therapeutics Ltd ACN 103 782 378 (“Company”). It does not purport to contain all the information that a prospective investor may require in connection with any potential investment in the Com
Slide 3: Company Overview
COMPANY OVERVIEW A global biopharmaceutical company developing, and marketing clinically validated For personal use only cannabis medicines. Global markets strategy Clinical validation focus Global product launch US, Australia and EU footprint to rapidly Leading pipeline of products in clinical Mult
Slide 4: Zelira's Global Commercialisation Strategy
ZELIRA’S GLOBAL COMMERCIALISATION STRATEGY For personal use only VA L U E A D D I N G • Clinically validated/Real World Data • Proprietary formulations • GMP-grade Branding Attracts Revenues from Global • IP protection • Branded Price Premium Distribution/Licensing Licensing (IP) Licensing strategy
Slide 5: Launch, Learn & Develop for Rapid Commercialisation
“LAUNCH, LEARN & DEVELOP” FOR RAPID COMMERCIALISATION For personal use only LAUNCH LEARN DEVELOP • Generate proprietary formulations • Collect real-world patient data • Patient data informs and de-risks design of clinical trial • Launch products in global markets • Refine product to meet patient nee
Slide 6: Multiple Product Launches Planned for 2020
For personal use only MULTIPLE PRODUCT LAUNCHES PLANNED FOR 2020 6
Slide 7: Zenivol: World's First Clinically Validated Cannabis Drug for Chronic Insomnia
ZENIVOL™: WORLD’S FIRST CLINICALLY VALIDATED CANNABIS DRUG FOR CHRONIC INSOMNIA For personal use only Z E N I V O L ™ : PAT H T O M A R K E T • Phase 1B/2A clinical trial confirmed Zenivol™ safe, efficacious and improved quality of life • 36% Reduction in Insomnia Symptoms Manufacturing agreement fo
Slide 8: Zenivol: Facilitates Traditional Targeted Marketing
™ ZENIVOL : FACILITATES TRADITIONAL TARGETED MARKETING S T R AT I F I C AT I O N O F PAT I E N T S / P R E S C R I B E R S Packaging Flyers For personal use only 1. 8
Slide 9: Global Market Opportunities
GLOBAL MARKET OPPORTUNITIES For personal use only AUSTRALIA GERMANY USA 25M 83M 330M 2019 population 2019 population 2019 population 11K 65K 4M Registered medical Registered medical Registered medical cannabis patients2 cannabis patients4 cannabis patients1 30-50K 90% Pennsylvania Louisiana Forecast
Slide 10: Hope for Autism
For personal use only ™ HOPE FOR AUTISM H OAutism P E ™ FTherapeutic O R A U T Market ISM • HOPE™ developed with and for the Autistic community • Survey suggests HOPE™ improves autism-related behaviors Revenues: Licensed in Pennsylvania & Louisiana (Deal Structure: Upfronts + double digit royalty) H
Slide 11: HOPE: Facilitates Traditional Targeted Marketing
For personal use only HOPE™: FACILITATES TRADITIONAL TARGETED MARKETING 1. 11
Slide 12: Rich Product Pipeline Launching in 2020
RICH PRODUCT PIPELINE LAUNCHING IN 2020 On-track to launch 5 products in 2020 For personal use only Launch Market 2020 2021 HOPE™ 1 & 2 for Autism Launched Revenues ZENIVOL™ for Insomnia Launched Oral Healthcare (2020) Aged Care (Parkinson’s) (2020) 12
Slide 13: New Product Launches Planned for 2021
NEW PRODUCTS LAUNCHES PLANNED FOR 2021 For personal use only Launch Market Peripheral Arterial Disease (2021) Revenues Dermatology (5 products) (2021) Oral Healthcare (2 products) (2021) Chronic Pain (Athletes) (2021) 13
Slide 14: Zelira's Five Sources of Revenues
Zelira’s Five Sources Of Revenues For personal use only LAUNCH & CLINICAL ORAL DERMATOLOGY PHARMA LEARN TRIALS HEALTH Autism Insomnia Toothpaste RX Pain Aged disorders Chronic Pain Mouth Wash Full Spec CBD GI Autism Consumer Brand OTC 14
Slide 15: Corporate Snapshot
CORPORATE SNAPSHOT FINANCIALS (as at 16 Oct 2020) For personal use only AUD$ Share Price $0.094 SHARE PRICE (as at 16 Oct 2020) 52w Range $0.022 - 0.010 Current shares on issue 1.18b Market Capitalisation $111m [US$78m] Cash (Sep 2020)* $9.6m Cash Burn (2020FY) $5.7m * Post $10.7m capital raise in A
Slide 16: Global Board of Directors
GLOBAL BOARD OF DIREC TORS UNITED STATES AUSTRALIA For personal use only Harry Karelis: Vice Chairman Osagie Imasogie: Chairman • Founding Director/Shareholder of numerous ASX-listed companies • Over 30 years in the field of law, finance, business management, including in the global medicinal cannab
Slide 17: Zelira Offers Investors Exposure to a Rapidly Emerging Global Industry
For personal use only ZELIRA THERAPEUTICS OFFERS INVESTORS EXPOSURE TO A RAPIDLY EMERGING GLOBAL INDUSTRY AT VERY ATTRACTIVE VALUATIONS AND SIGNIFICANT VALUE DRIVERS OVER THE NEXT 3-18 MONTHS 17
Zelira Therapeutics — Non-Deal Roadshow (October 2020) on 6ix